Protocol for a multicenter, prospective, real‐world study: Lecanemab in patients with early Alzheimer's disease(LEAD) in China
The LEAD project is a multi-center, real-world study that will determine the therapeutic efficacy of lecanemab in alleviating clinical symptoms and pathological aspects in Alzheimer's disease patients in Jiangsu, China, as well as monitor adverse effects, in order to assist the treatment of more Asian AD patients.
Authors
- Dan Yang (ORCID: https://orcid.org/0000-0002-8795-6122)
- Nihong Chen
- Limoran Tang
- Hui Zhao (ORCID: https://orcid.org/0000-0002-3136-8559)
- Yun Xu
Institutions
- Nanjing Drum Tower Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101524
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00